STING

Byaibio

STING (tmem173) is an innate immune pathway mediator that links cytosolic nucleic-acid sensing to type I interferon signaling, and it is activated downstream of cgas sting and by cyclic dinucleotides. Its primary function is to drive IFN-I responses and broader antitumor immunity, which is why it is repeatedly pursued as a cancer immunotherapy target; the Key Facts also note that it mediates ATR inhibitor–induced Galectin-9 upregulation. Recent studies highlight activation strategies including the STING agonist diABZI, non-CDN agonists, bifunctional agonists, and delivery platforms such as MOFs, silicasomes, and hydrogel-liposome composites. Beyond oncology, STING/cGAS-STING signaling has been implicated in Parkinson’s disease, and promoter hypomethylation with higher mRNA expression in renal cell carcinoma correlated with immune infiltration, clinicopathologic features, and poor overall survival. Overall, the literature supports STING as a central TMEM173-encoded immune adaptor whose activation can be therapeutically leveraged, but whose expression and epigenetic regulation may also carry prognostic value.

Cancer immunotherapy

  • STING is a target for cancer immunotherapy, and co-delivery of a STING agonist with IDO1 blockade enhanced activation of type I dendritic cells in cancer (PMID:41702511).
  • A cyclic dinucleotide delivery system in oral cancer was designed to control release of a STING agonist, underscoring STING as a druggable innate immune target (PMID:41702512).
  • A STING agonist diABZI was used to enhance antitumor immunity, consistent with STING pathway activation as an immunostimulatory strategy (PMID:41723989).
  • A bifunctional STING agonist was developed to overcome STING-driven immunosuppression and improve antitumor immunity (PMID:42017623).
  • Reviews and translational studies describe non-CDN and benzimidazole-derived STING agonists as promising alternatives for cancer immunotherapy (PMID:41785706, PMID:41955504).

Tumor delivery systems and preclinical activation

  • Cryoablation activated STING-dependent type I interferon pathways in preclinical models, linking local tumor ablation to innate immune priming (PMID:41989053).
  • A Mn(III)-tuned nanozyme system activated the STING pathway as part of multimodal tumor immunotherapy (PMID:41512497).
  • Engineered silicasome delivery enabled systemic STING agonist administration for potent antitumor immunotherapy (PMID:41955504).
  • A “self” signal-suppressed MOF nanodrug enhanced melanoma immunotherapy via CD47 blockade and STING-related immune activation (PMID:41723989).
  • Intracellular DNA network assembly was used to hyperactivate STING for imaging-guided immune activation (PMID:41724120).

Disease association and regulation

  • In renal cell carcinoma, STING promoter hypomethylation and increased mRNA expression were associated with immune cell infiltration, clinicopathologic features, and poor overall survival (PMID:41942521).
  • STING signaling was discussed as a downstream mediator of cGAS-driven IFN-I responses in Parkinson’s disease mechanisms and therapeutic strategies (PMID:41500413).
  • Methionine depletion by engineered probiotics activated the STING pathway and improved PD-L1 antibody immunotherapy, showing metabolic control of STING signaling (PMID:41604978).
  • ATR inhibitor treatment upregulated Galectin-9 through an innate immune pathway mediated by STING, linking DNA damage response to immune modulation (PMID:41651398).